Issue Information.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 6, p. 1, doi. 10.1002/cai2.83
- Publication type:
- Article
Works matching IS 27709183 AND DT 2024 AND VI 3 AND IP 6
Results: 9
1
2
Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 6, p. 1, doi. 10.1002/cai2.155
- By:
- Publication type:
- Article
3
Leukocyte immunoglobulin‐like receptor B4: A keystone in immune modulation and therapeutic target in cancer and beyond.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 6, p. 1, doi. 10.1002/cai2.153
- By:
- Publication type:
- Article
4
Prognostic nomograms for young breast cancer: A retrospective study based on the SEER and METABRIC databases.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 6, p. 1, doi. 10.1002/cai2.152
- By:
- Publication type:
- Article
5
Impact of metallic nanoparticles on gut microbiota modulation in colorectal cancer: A review.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 6, p. 1, doi. 10.1002/cai2.150
- By:
- Publication type:
- Article
6
Retinoic acid receptor responder 2 and lipid metabolic reprogramming: A new insight into brain metastasis.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 6, p. 1, doi. 10.1002/cai2.148
- By:
- Publication type:
- Article
7
TRIP13: A promising cancer immunotherapy target.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 6, p. 1, doi. 10.1002/cai2.147
- By:
- Publication type:
- Article
8
Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 6, p. 1, doi. 10.1002/cai2.143
- By:
- Publication type:
- Article
9
Development and validation of the NCC‐BC‐A scale to assess patient‐reported outcomes for breast cancer patients in China.
- Published in:
- Cancer Innovation, 2024, v. 3, n. 6, p. 1, doi. 10.1002/cai2.141
- By:
- Publication type:
- Article